Hub overviewParaneoplasticICD-10 various

Paraneoplastic skin signs — overview

Paraneoplastic dermatoses · cutaneous paraneoplastic syndromes

Paraneoplastic skin signs are dermatological manifestations of an underlying internal malignancy that are not caused by direct invasion, metastasis or treatment. Their recognition is a powerful diagnostic clue, sometimes preceding the cancer by months. UK clinical practice groups them by morphology and underlying cancer association. This page is a navigational hub linking to individual monographs.

CurrentLast reviewed 16 May 2026

Concept and criteria

  • Curth (1976) criteria for paraneoplastic dermatoses:
    1. Concurrent onset with malignancy.
    2. Parallel course (skin sign improves with tumour treatment; recurs with relapse).
    3. Specific tumour-skin association.
    4. Statistical link.
    5. Genetic syndrome association — the most variably reported criterion; the first four are the core Curth postulates.
  • Strong vs weak paraneoplastic associations vary; some are diagnostic of malignancy until proven otherwise.

Classical paraneoplastic dermatoses

Cancer-specific associations

  • Internal adenocarcinoma (GI / lung): acanthosis nigricans, tripe palms, sign of Leser-Trélat, erythema gyratum repens, acquired hypertrichosis lanuginosa, Trousseau.
  • Lymphoma / haematological: acquired ichthyosis (Hodgkin), pruritus of malignancy, paraneoplastic pemphigus (NHL / CLL / Castleman), anetoderma, erythroderma.
  • Upper aerodigestive SCC: Bazex acrokeratosis, Howel-Evans.
  • Plasma cell dyscrasia / myeloma: POEMS, scleromyxoedema, necrobiotic xanthogranuloma.
  • Solid organ malignancy: dermatomyositis, eruptive xanthomas (rare), migratory thrombophlebitis.
  • MEN-2B / endocrine: mucosal neuromas, cafe-au-lait, ganglioneuromatosis.

Workup when paraneoplastic suspected

  • Full history including B-symptoms (weight loss, night sweats, fever), recent skin change, systems review, family history.
  • Full skin and mucosal examination; lymphadenopathy; hepatosplenomegaly.
  • Bloods: FBC, U&E, LFT, CRP, ESR, LDH, calcium, ferritin, thyroid function, serum / urine protein electrophoresis.
  • HIV, HBV / HCV, HTLV-1 (lymphoma).
  • Age- / sex-appropriate cancer screening — mammography, cervical, FIT / colonoscopy, gastroscopy if symptoms.
  • CT chest / abdomen / pelvis if persistent unexplained / B-symptoms.
  • PET-CT for suspected lymphoma / occult primary.
  • Skin biopsy of any persistent / atypical lesion with appropriate IHC.

Practical points

  • Threshold for malignancy workup should be low when classical paraneoplastic sign present.
  • Time-course: paraneoplastic sign may precede cancer diagnosis by months (acanthosis nigricans, AHL, EGR).
  • Resolution with cancer treatment is supportive evidence.
  • Communicate to GP / cancer MDT promptly; document red-flag rationale.
  • NICE NG12 (suspected cancer): generalised >6 weeks pruritus, unexplained lymphadenopathy, weight loss → 2-week-wait referral consideration.

References

  1. Curth HO. Skin lesions and internal carcinoma. Cancer Med. 1976.
  2. Boyce S, Harper J. Paraneoplastic dermatoses. Dermatol Clin. 2002;20:523-532.
  3. Yuste-Chaves M, Unamuno-Pérez P. Cutaneous alerts in systemic malignancy. Actas Dermosifiliogr. 2013;104:285-298.
  4. NICE NG12. Suspected cancer: recognition and referral. London: NICE; 2015 (last updated 15 April 2026).

Spot a correction?

If any clinical statement, citation or link on this page needs updating, please email admin@skinoncology.net with the page name, the proposed correction and the supporting source.